|

Autologous CD7 CAR T-cell Clinical Trials

1 actively recruiting trial

Pipeline

Phase 1/2: 1

Top Sponsors

  • Beijing GoBroad Hospital1

Indications

  • T-cell Malignancies1
  • Refractory Acute Lymphoblastic Leukemia1
  • Acute Lymphoblastic Leukemia, in Relapse1
  • T-cell Acute Lymphoblastic Leukemia1
  • Cancer1

Other1 trial

Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.